Document is current
Any future updates will be listed below
-
Authors
Sampson, John H. http://orcid.org/0000-0002-0104-7658
Gunn, Michael D. http://orcid.org/0000-0003-4602-0667
Fecci, Peter E. http://orcid.org/0000-0002-2912-8695
Ashley, David M.
- License Information
-
More Information
Article History
Accepted: 25 October 2019
First Online: 5 December 2019
Competing interests
: J.H.S. has an equity interest in Annias Immunotherapeutics, which has licensed intellectual property from Duke related to the use of the PEP-CMV vaccine in the treatment of glioblastoma. J.H.S. has an equity interest in Istari Oncology, which has licensed intellectual property from Duke related to the use of polio virus and D2C7 in the treatment of glioblastoma. J.H.S. has additional relationships with Celldex (intellectual property, royalties) and Medicenna Therapeutics (consulting). J.H.S. is an inventor on patents related to the PEP-CMV DC vaccine with tetanus, as well as to polio virus vaccine and D2C7 in the treatment of glioblastoma. D.M.A is an inventor on patents related to the use of polio virus. M.D.G is an inventor on patents related to cellular vaccines. Duke and certain Duke investigators could benefit financially if related therapies prove effective and are commercially successful. P.E.F. has no relevant disclosures.
